Brainstorm Cell (Germany) Performance
| GHDN Stock | EUR 2.69 0.00 0.00% |
The firm shows a Beta (market volatility) of -0.11, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Brainstorm Cell are expected to decrease at a much lower rate. During the bear market, Brainstorm Cell is likely to outperform the market. At this point, Brainstorm Cell Ther has a negative expected return of -0.57%. Please make sure to confirm Brainstorm Cell's coefficient of variation, variance, and the relationship between the mean deviation and standard deviation , to decide if Brainstorm Cell Ther performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Brainstorm Cell Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's fundamental indicators remain nearly stable which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 37.8 M | |
| Total Cashflows From Investing Activities | 323 K |
Brainstorm |
Brainstorm Cell Relative Risk vs. Return Landscape
If you would invest 404.00 in Brainstorm Cell Therapeutics on September 1, 2024 and sell it today you would lose (135.00) from holding Brainstorm Cell Therapeutics or give up 33.42% of portfolio value over 90 days. Brainstorm Cell Therapeutics is producing return of less than zero assuming 3.327% volatility of returns over the 90 days investment horizon. Simply put, 29% of all stocks have less volatile historical return distribution than Brainstorm Cell, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Brainstorm Cell Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Brainstorm Cell's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Brainstorm Cell Therapeutics, and traders can use it to determine the average amount a Brainstorm Cell's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1699
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GHDN |
Estimated Market Risk
| 3.33 actual daily | 29 71% of assets are more volatile |
Expected Return
| -0.57 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.17 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Brainstorm Cell is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Brainstorm Cell by adding Brainstorm Cell to a well-diversified portfolio.
Brainstorm Cell Fundamentals Growth
Brainstorm Stock prices reflect investors' perceptions of the future prospects and financial health of Brainstorm Cell, and Brainstorm Cell fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Brainstorm Stock performance.
| Return On Equity | -1.93 | |||
| Return On Asset | -0.68 | |||
| Current Valuation | 44.56 M | |||
| Shares Outstanding | 36.54 M | |||
| Price To Book | 36.30 X | |||
| EBITDA | (24.28 M) | |||
| Cash And Equivalents | 6.22 M | |||
| Cash Per Share | 0.29 X | |||
| Total Debt | 3.04 M | |||
| Debt To Equity | 934.00 % | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (26.27 M) | |||
| Earnings Per Share | (0.68) X | |||
| Total Asset | 29.28 M | |||
About Brainstorm Cell Performance
By analyzing Brainstorm Cell's fundamental ratios, stakeholders can gain valuable insights into Brainstorm Cell's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Brainstorm Cell has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Brainstorm Cell has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York. BRAINSTORM operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 31 people.Things to note about Brainstorm Cell Ther performance evaluation
Checking the ongoing alerts about Brainstorm Cell for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Brainstorm Cell Ther help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Brainstorm Cell Ther generated a negative expected return over the last 90 days | |
| Brainstorm Cell Ther has high historical volatility and very poor performance | |
| Brainstorm Cell Ther has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Brainstorm Cell Therapeutics has accumulated 3.04 M in total debt with debt to equity ratio (D/E) of 934.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Brainstorm Cell Ther has a current ratio of 0.95, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Brainstorm Cell until it has trouble settling it off, either with new capital or with free cash flow. So, Brainstorm Cell's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Brainstorm Cell Ther sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Brainstorm to invest in growth at high rates of return. When we think about Brainstorm Cell's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (24.46 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Brainstorm Cell Therapeutics has accumulated about 6.22 M in cash with (26.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29. | |
| Roughly 23.0% of Brainstorm Cell shares are held by company insiders |
- Analyzing Brainstorm Cell's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Brainstorm Cell's stock is overvalued or undervalued compared to its peers.
- Examining Brainstorm Cell's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Brainstorm Cell's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Brainstorm Cell's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Brainstorm Cell's stock. These opinions can provide insight into Brainstorm Cell's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Brainstorm Stock analysis
When running Brainstorm Cell's price analysis, check to measure Brainstorm Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brainstorm Cell is operating at the current time. Most of Brainstorm Cell's value examination focuses on studying past and present price action to predict the probability of Brainstorm Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brainstorm Cell's price. Additionally, you may evaluate how the addition of Brainstorm Cell to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |